Showing 3861-3870 of 5910 results for "".
- New “Eying the Future" School Program Seeks to Fuel Student Interest in Optometryhttps://modernod.com/news/new-eying-the-future-school-program-seeks-to-fuel-student-interest-in-optometry/2482568/Latinos en Optometry has partnered with Transitions Optical to launch "Eying the Future," a free in-school educational program specifically designed to inspire middle and high school students in Latino communities to consider
- Outlook Therapeutics Receives NICE Recommendation of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-receives-nice-recommendation-for-lytenava-as-a-treatment-for-wet-amd/2482567/The UK’s National Institute for Health and Care Excellence (NICE) has recommended Lytenava (bevacizumab gamma) as an option for the treatment of wet AMD in adults. This marks the first positive reimbursement decision for Lytenava worldwide and supports its commercializat
- Galimedix Begins Phase 1 Clinical Trial of Oral GAL-101 for Neuroprotective Treatmenthttps://modernod.com/news/galimedix-therapeutics-begins-phase-1-clinical-trial-of-oral-gal-101-for-neuroprotective-treatment/2482565/Galimedix Therapeutics announced the first volunteers have been dosed in the company’s phase 1 study of oral GAL-101, an amyloid beta (Aβ) aggregation modulator. This trial is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses
- EyePoint Announces First Patient Dosed in Phase 3 LUCIA Trial of Duravyu for Wet AMDhttps://modernod.com/news/eyepoint-announces-first-patient-dosed-in-phase-3-lucia-trial-of-duravyu-for-wet-amd/2482563/EyePoint Pharmaceuticals announced that the first patient has been dosed in the LUCIA trial. This is the second global phase 3 clinical trial evaluating Duravyu (formerly EYP-1901), a sustained-delivery therapy for treating wet age-related macular degeneration (AMD). Duravyu is an inves
- Nicole Skibinski Appointed Chief Executive Officer of Fluorescene Mediahttps://modernod.com/news/nicole-skibinski-appointed-chief-executive-officer-of-fluorescene-media/2482562/Nicole Skibinski was appointed Chief Executive Officer of Fluorescene Media, which aims to help optometry professionals connect, learn, and thrive. Ms. Skibinski has more than 20 years of leadership in the eye care and health care industries, with experience in
- Nidek Launches NP-T Preloaded Toric IOL Injection Systemhttps://modernod.com/news/nidek-launches-np-t-preloaded-toric-iol-injection-system/2482560/Nidek announced the international launch of its NP-T Preloaded Toric IOL Injection System. Previously available exclusively in Japan, the system is now available globally. The NP-T system is designed to combine precision engineering with user-friendly design, featuring a prelo
- FDA Clears Novoxel's Tixel for the Treatment of Meibomian Gland Dysfunctionhttps://modernod.com/news/fda-clears-novoxels-tixel-for-the-treatment-of-meibomian-gland-dysfunction/2482559/Isreal-based Novoxel announced the the FDA clearance of its Tixel device for application of localized heat and pressure for patients with evaporative dry eye due to meibomian gland dysfunction (MGD). The Tixel systems use proprietary Thermo-Mechanical Actio
- Scientists Use Gene Editing to Treat Retinitis Pigmentosa in Micehttps://modernod.com/news/scientists-use-gene-editing-to-treat-retinitis-pigmentosa-in-mice/2482558/Researchers funded by the National Eye Institute (NEI) have successfully used a gene-editing technique to correct a mutation responsible for retinitis pigmentosa (RP). The study, led by Krzysztof Palczewski, PhD, of the University of California
- Johnson & Johnson Appoints Shawn Millerick President, Vision Care, Americashttps://modernod.com/news/johnson-johnson-appoints-shawn-millerick-president-vision-care-americas/2482556/Johnson & Johnsonhas announced the appointment of Shawn Millerick as President, Vision Care, Americas, effective November 11, 2024. Mr. Millerick will be responsible for defining strategy and driving growth for Johnson & Johnson’s Vision Care portfolio in North Americ
- Melt Pharmaceuticals Announces Positive Phase 3 Trial Results for MELT-300 Sedation Solutionhttps://modernod.com/news/melt-pharmaceuticals-announces-positive-phase-3-trial-results-for-melt-300-sedation-solution/2482552/Melt Pharmaceuticals announced positive topline results from its pivotal phase 3 trial of MELT-300. This novel, non-intravenous, non-opioid tablet is designed to provide effective sedation during cataract surgery. The phase 3 study, conducted under a Special Protocol Assessment (SPA) ag